24/7 Market News Snapshot 13 February, 2025 – Genprex, Inc. Common Stock (NASDAQ:GNPX)

February 13, 2025

DENVER, Colo., 13 February, 2025 (247marketnews.com) – (NASDAQ:GNPX) are discussed in this article.
Genprex, Inc. (GNPX) has experienced a significant bullish trend recently, with shares trading at $0.513 in the pre-market session, marking a 7.82% increase from the previous close of $0.476. The trading volume has surged to 5.99 million shares, indicating heightened investor interest, potentially driven by positive developments surrounding the company. Investors are advised to observe key technical indicators, such as Moving Averages, which may further validate this upward trend. Notable resistance levels have been identified around $0.55, with support anticipated near $0.48, suggesting that GNPX could be on the verge of sustained momentum in the coming trading hours.

In a promising development, Genprex has announced significant advancements in cancer therapy, particularly through a recent publication by its research collaborators, showcasing the potential of NPRL2 gene therapy in targeting anti-PD1 resistant non-small cell lung cancer (NSCLC). Featured in the esteemed journal eLife, the study reveals that NPRL2, delivered via Genprex’s innovative Oncoprex® Delivery System, demonstrates remarkable efficacy in treating KRAS/STK11 mutant metastatic NSCLC.

Ryan Confer, President and CEO of Genprex, expressed optimism about these findings, emphasizing the therapeutic promise of the Oncoprex Delivery System. He stated that the results validate its applicability beyond TUSC2 to include NPRL2, paving the way for broader clinical development initiatives.

The study’s findings indicate that NPRL2 gene therapy alone produces significant antitumor effects in humanized mouse models, while its combination with pembrolizumab, an existing immunotherapy, offers minimal additional benefit. This positions NPRL2 as a potential standalone treatment for challenging cancer types resistant to traditional therapies.

Genprex remains committed to advancing innovative treatment options for cancer patients, and these developments reinforce its strategic direction and mission to provide hope through groundbreaking gene therapy solutions.

Related news for (GNPX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.